We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide.We work with civil society groups and networks at local, regional and global levels, sharing evidence and identifying opportunities to influence health-related decisions. Our collective advocacy aims to build momentum and drive changes that reduce inequities and improve the health of millions of people worldwide. About this study Intergenerational programs that bring pre-school

About this study Intracerebral haemorrhage (ICH), bleeding into the brain, is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur in the world each year. Patients fortunate enough to survive an ICH are at very high risk of another ICH as well as heart attacks and other serious heart-related events. Whilst there is strong evidence that these risks can be reduced by good control of blood pressure (BP), many patients do not receive any BP lowering treatment or that this treatment is inadequate. TRIDENT aims to determine the benefits of using three different BP medications (each at half the normal dose) in a single pill on preventing another stroke. This capsule with the three medications, is called the Triple Pill. The study is hoping to enrol and treat 1500 people. Recruitment criteria Inclusion criteria Adults with a history of ICH stroke Average resting BP in the 130-160 mmHg range

About this study People with advanced kidney disease or those receiving dialysis often have other diseases related to the heart, brain and blood vessels, known as vascular disease (for example, heart attack, stroke and poor blood circulation). However, few treatments have been proven to prevent these conditions in people with advanced kidney disease. Blood thinners (medicines that prevent blood clots) are frequently used and proven to help other groups of people who are at high risk of vascular disease. There is little understanding of whether blood thinners provide similar benefits in people with advanced kidney disease. The aim of the TRACK study is to find out whether a low dose of blood thinning medicine can reduce heart and vascular disease better than placebo (a look alike tablet that contains no active medication) in people with advanced kidney disease. Recruitment criteria Inclusion: Age ≥18 years, Advanced kidney disease (kidney failure on dialysis, or